Project ID: BP-20240430-L-EE-84
IPF: A Growing Global Health Concern
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and irreversible interstitial lung disease with a median survival rate of only three to five years after diagnosis. Globally, the number of IPF patients is estimated to be in the millions, with the disease affecting approximately 10 to 20 per 100,000 people, though this can vary by region.
The current treatment landscape for IPF primarily revolves around antifibrotic medications, such as pirfenidone and nintedanib, which aim to slow disease progression. However, these treatments do not halt or reverse the fibrosis, and there remains a significant unmet need for therapies that can improve lung function and patient quality of life.
The market size for IPF treatments is substantial, reflecting the high unmet medical need and the limited options for patients. Despite the availability of approved therapies, the clinical demand is far from being satisfied, particularly for patients with rapidly progressing disease or those who do not respond to existing treatments.
Innovative drug development for IPF is actively underway, with a focus on targeting the underlying pathophysiological processes, such as fibroblast activation, inflammation, and the TGF-β signaling pathway. Several new drugs are in various stages of clinical development, offering hope for more effective treatments in the future. These include medications that target the NLRP3 inflammasome, JAK inhibitors, and anti-CTGF antibodies, among others.
The advancement of these new therapies is crucial for improving the prognosis of IPF patients and potentially transforming the standard of care for this devastating disease.
Request from MNC
Molecular Entities: Large Molecules, Small Molecules, RNA, In Vivo Cell Therapy
Current Stage: Preclinical, Phase I Clinical
Interest in Rights: Global Rights
Collaboration Model: License
How to Contact
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
